Role of radiation therapy in gastric adenocarcinoma

Table 4 Prospective trials of pre-operative chemoradiation in gastric cancer

RT dose Overall Median Complete Partial R0 % Distant
Reference Chemo (Gy) survival % survival time response (%) response (%) rate (%) metastases
(2 yr) (mo) during therapy
RTOG	5FU/LV/cis×2 prior to RT;
99-04[46]	5FU with RT	45	NR	NR	27	NR	77	NR
(n = 49)
Roth[45]		31.2,
(n = 19)	Cis/5FU	38.4,	71	NR	5	50	NR	0
		45.61
Lowy[41]
(n = 23)	5FU	45	NR	NR	11	63	NR	17
Ajani 2004[43]
(n = 33)	5FU/LV/cis×2 prior to RT; 5FU with RT	45	54	33.7	30	24	NR	12
Ajani 2005[44]
(n = 41)	5FU/cis/tax×2 prior to RT; 5FU/tax with RT	45	682	Not reached	20	153	78	0
Balandraud[47]
(n = 42)	5FU/cis	45	45.6	23	14	-	81	-
Klautke[67]
(n = 21)	Cis/5FU or tax	50.4	42	18	14	62	53	-

Abbreviations: Cis = cisplatin, 5FU = 5-fluorouracil, LV = leucovorin, tax = paclitaxol, RT = radiation therapy, R0 = resection with negative margins.

¹Given 1.2 Gy b.i.d. in a phase I dose escalation trial;

²At a median follow-up of 36 mo;

³PR defined as <10% residual cells in resected specimen.